EP2911648 - Bibliographic data

COMPOSITION PHARMACEUTIQUE STABLE DE 5-AZA-2'-DÉSOXYCITIDINE

Last update 11/07/2025
Legal status Brevet déchu
Origin Euro-PCT
(73) Holder

Fresenius Kabi Oncology Limited

B- 310, Som Datt Chambers - I Bhikaji Cama Place
New Delhi 110 066
Inde
(72) Inventors

Dhiraj KHATTAR

Fresenius Kabi Oncology Limited Echelon Institutional Area Plot No.11 Sector 32
Gurgaon 122001 Haryana
Inde

Rajesh KHANNA

Fresenius Kabi Oncology Limited Echelon Institutional Area Plot No.11 Sector 32
Gurgaon 122001 Haryana
Inde

Sanjay MOTWANI

Fresenius Kabi Oncology Limited Echelon Institutional Area Plot No.11 Sector 32
Gurgaon 122001 Haryana
Inde

Sunny CHOPRA

Fresenius Kabi Oncology Limited Echelon Institutional Area Plot No.11 Sector 32
Gurgaon 122001 Haryana
Inde

Minakshi GARG

Fresenius Kabi Oncology Limited Echelon Institutional Area Plot No.11 Sector 32
Gurgaon 122001 Haryana
Inde
(74) Agent

Mail recipient

Fresenius Kabi Deutschland GmbH

Patent Department Borkenberg 14
61440 Oberursel
Allemagne
(21) Request number EP13814236.9
(22) Request date 24/10/2013
(11) Publication number EP2911648
Publication date 01/02/2017
(54) Title of the invention COMPOSITION PHARMACEUTIQUE STABLE DE 5-AZA-2'-DÉSOXYCITIDINE
(51) International classification A61K  47/10, A61K  47/18, A61K 31/706, B65B 7/16, A61K 9/00, A61K 9/08, A61K 31/7068, B65B 3/00
International classification (before reform) None
Claimed priority

(31) Number: 3284DE2012
(32) Date: 25/10/2012
(33) Country: IN

Initial application None
Divisional application None
Expected annuity Annuity: 5 - Amount: 85 € - Due date 31/10/2017
Surtax: 5 - Amount: 17 € - Due date 02/05/2018
Last annuity None
Publication None
History

Publication de la délivrance du brevet européen - Legal date 01/02/2017

Modification des informations de priorité du brevet européen - Legal date 17/03/2017

Entrée en période de grâce du brevet d'invention - Legal date 01/11/2017

Déchéance du brevet d'invention après période de grâce - Legal date 31/10/2017